Trius Therapeutics Sets IPO Terms

Trius Therapeutics Inc., a San Diego-based developer of antibacterial drugs, has set its IPO terms to six million common shares being offered at between $12 and $14 per share. The company would have an initial market cap of approximately $233 million, were it to price at the high end of its offering range.

Trius plans to trade on the Nasdaq under ticker symbol TSRX, with Credit Suisse serving as lead underwriter.

The company has raised nearly $50 million in VC funding, from firms like Sofinnova Ventures (21.2% pre-IPO stake), Interwest Partners (17.7%), Versant Ventures (17.7%), Prism VentureWorks (13.5)%, Kleiner Perkins Caufield & Byers (11.9%) and FinTech Global Capital.